The BCD-178-1 clinical study will evaluate the pharmacokinetics, safety, and immunogenicity of BCD-178 and Perjeta® in healthy volunteers.
Participation of a maximum of 100 people in the Russian Federation has been approved for this study.
The BCD-178-1 study is conducted at 2 study centers in the city of Saint Petersburg.
You can ask questions about participation in the clinical study and request contact information about study centers using a special form «Do you have any questions?».
Authorization of the Ministry of Health of the Russian Federation for this clinical study, No. 460 dated July 27, 2022, and the list of approved study centers have been published in the State Register of Medicines.